What did RBC change in the REGN analyst rating on Mar 02, 2026?

RBC Capital maintained the REGN analyst rating at Sector Perform on Mar 02, 2026 and raised the price target to **$765**. The firm kept a neutral stance while improving its valuation view.

How should investors interpret a Sector Perform REGN analyst rating?

Sector Perform suggests neutral expected returns versus peers. Investors should weigh the rating against catalysts and fundamentals and avoid aggressive buying based solely on this neutral view.

What is Meyka AI’s view after the REGN analyst rating change?

Meyka AI rates REGN with a grade of **A**, reflecting benchmark and sector metrics plus analyst consensus. The grade supports a positive long-term view but is not investment advice.

Where can I read the original analyst note and market quote?

RBC’s summary of the REGN analyst rating and PT lift is available on StreetInsider. A recent market quote is available on MarketWatch. Both sources track the March 02, 2026 update.

Analyst Ratings

RBC Maint. REGN (Regeneron Pharmaceuticals, Inc.) at Sector Perform, PT $765 Mar 2026

ByDanny Kontos March 3, 2026

RBC Capital maintained REGN at Sector Perform on Mar 02, 2026. The firm raised its price target to $765. This REGN analyst rating reflects RBC’s view on near-term sales and the company pipeline. RBC’s note arrived before markets opened and coincided with a 1.44% ($11.24) move in the stock since the update. Meyka AI’s real-time system recorded the change and flagged the firm’s neutral stance for investors.